Inclusion Criteria:

        Part A

          -  Patients with any previously treated solid tumor-type other than hepatocellular
             carcinoma or intrahepatic cholangiocarcinoma that is advanced, or recurrent and
             progressing since last anti-tumor therapy, and for which no alternative, standard
             therapy exists.

          -  Prior chemotherapy, radiation therapy or immunotherapy must have been completed at
             least 4 weeks prior to the administration of the first dose of study drug, and patient
             has recovered

        Part B:

          -  Patients with Non-small Cell Lung Cancer (NSCLC) or other protocol-specified solid
             tumors with locally advanced or metastatic, non-resectable disease, which has
             progressed despite treatment with first-line standard-of-care treatment, or first- and
             second-line treatment, dependent on expansion cohort.

          -  Prior therapy must have been completed 2-4 weeks prior to the administration of the
             first dose of study drug as specified per protocol according to type of prior therapy.

        Exclusion Criteria:

          -  Patient previously had known immediate or delayed hypersensitivity reaction or
             idiosyncrasy to the excipients

          -  Part A: Treatment with any PD-1, or Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4
             directed antibody, or with any other immunotherapy within 4 weeks prior to initiation
             of the study drug.

          -  Part A: Use of other biological investigational drugs (drugs not marketed for any
             indication), including use of investigational drugs targeting CD137/4-1BB within at
             least 5 half-lives (or within 8 weeks, whatever is longer) prior to the administration
             of the first dose of study drug.

          -  Part B: As defined per protocol for each expansion cohort, has not been treated with
             specified first/second-line standard-of-care therapies biological drugs (marketed or
             investigational) for treatment of the current cancer, or has not adequately recovered
             from AEs that occurred with prior therapy.

          -  Patient has an active autoimmune disease or a documented history of autoimmune
             disease.